TI
IRLA

Trexquant Investment’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Trexquant Investment’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-21
Closed -$385K – 1570
2021
Q3 		$385K Buy
+21
New +$334K 0.03% 642
2021
Q2 		– Sell
-57
Closed -$407K – 1427
2021
Q1 		$407K Buy
+57
New +$410K 0.04% 603

Other funds holding IRLA

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Trexquant Investment's IRLA Position: Q4 2021 in Review

Trexquant Investment sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q4 2021, closing a stake of 21 shares — an estimated $385K sold.

Trexquant Investment first reported a position in IRLA in Q1 2021 and held it in 2 quarters. The position peaked at $407K in Q1 2021. 98 funds tracked by Wall St. Rank hold IRLA as of Q4 2021.

  • Trexquant Investment reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Trexquant Investment sold 21 IRulya Therapeutics Inc. Common Stock shares in Q4 2021, an estimated $385K.
  • Trexquant Investment first reported a position in IRulya Therapeutics Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Trexquant Investment's IRulya Therapeutics Inc. Common Stock position peaked at $407K in Q1 2021.
  • 98 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q4 2021.

Based on Trexquant Investment's 13F filing for Q4 2021, filed 14 Feb 2022.